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Risk of endometrial cancer after tamoxifen treatment of breast
cancer
Summary
Since large trials have been set up to assess whether
tamoxifen decreases the risk of breast cancer in healthy
women, it has become important to investigate the drug’s
potential adverse effects, including occurrence of endometrial
cancer. We undertook a case-control study in the Netherlands
to assess the effect of tamoxifen on the risk of endometrial
cancer after breast cancer.
Through the population-based Netherlands Cancer Registry
and two older, hospital-based, registries, we identified 98
patients who had endometrial cancer diagnosed at least 3
months after a diagnosis of primary breast cancer. Detailed
information about treatment was obtained for all these
patients, and for 285 controls, who were matched to the cases
for age, year of breast cancer diagnosis, and survival time with
intact uterus. Tamoxifen had been used by 24% of patients
with subsequent endometrial cancer and 20% of controls
(relative risk 1&middot;3 [95% Cl 0&middot;7-2&middot;4]). Women who had used
tamoxifen for more than 2 years had a 2 3 (0 9-5 9) times
greater risk of endometrial cancer than never users. There was
a significant trend of increasing risk of endometrial cancer with
duration of tamoxifen use (p=0 049), and also with
cumulative dose (p=0&middot;046). The duration-response trends
were similar with daily doses of 40 mg or 30 mg and less.
These findings support the hypothesis that tamoxifen use
increases the risk of endometrial cancer. This oestrogenic
effect on the endometrium was not related to the dose
intensity. Physicians should be aware of the higher risk of
endometrial cancer in tamoxifen users.
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Introduction
Since its introduction in the early 1970s, tamoxifen has been
widely and effectively used to treat advanced breast cancer.
Adjuvant tamoxifen therapy in early-stage breast cancer
became common in the 1980s, and has been convincingly
shown to improve disease-free survival as well as overall
survival for women older than 50 years.’ Several large trials
have suggested, furthermore, that tamoxifen reduces the
risk of cancer in the contralateral breast." Based on these
findings, chemoprevention trials have been set up in the
USA and Europe to find out whether tamoxifen decreases
the risk of breast cancer developing in healthy women
judged to be at high risk of the disease.5.6
Our knowledge of the long-term effects of tamoxifen is
still limited. Tamoxifen’s mixed oestrogen-agonist and
oestrogen-antagonist properties have led to concern that
the drug may increase the risk of endometrial cancer. The
Stockholm trial4 found that women receiving 40 mg
tamoxifen daily for at least 2 years had a more than six-fold
excess risk of endometrial cancer in comparison with
untreated controls. No significant increase in risk has been
reported in other major adjuvant trials although a
non-significant excess of endometrial cancer after
tamoxifen treatment was noted in an evaluation of Danish
trials and in an unpublished Southwest Oncology Group
Trial.8-10 The 10-year cumulative risk of endometrial
cancer in postmenopausal women is estimated to be 0 3% or
less. Thus, a follow-up study with sufficient power to settle
the question of whether there is an excess risk of
endometrial cancer after tamoxifen treatment would
require long-term follow-up of many thousands of breast
cancer patients. We therefore used a case-control design to
investigate, in a nationwide study, whether tamoxifen, at
different doses and for different durations, increases the
risk of endometrial cancer.
Patients and methods
Since 1989, the Netherlands has had a population-based,
nationwide cancer registry served by nine regional cancer
registries." Most registries have been operating since 1986, the
Eindhoven Cancer Registry since 1975,12 and the Middle
Netherlands Breast Cancer Registry since 1973.13 Patients with
endometrial cancer after breast cancer were identified from eight of
the nine regional cancer registries; other cases (most with
endometrial cancer diagnosed before 1986) were identified from
the hospital tumour registries of two major cancer treatment
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centres (the Netherlands Cancer Institute [NKI], Amsterdam, and
the Dr Daniel den Hoed Cancer Center [DDHK], Rotterdam).
Women were eligible for the study if they had a histologically or
cytologically confirmed diagnosis of infiltrating endometrial
carcinoma at least 3 months after a diagnosis of primary breast
cancer; if the breast cancer developed after Jan 1, 1976 (Jan 1, 1972
in NKI and DDHK; before these dates tamoxifen was not
commonly used); and if they had no other second malignant
disorder after breast cancer, except for carcinoma in situ of the
uterine cervix, basal-cell carcinoma of skin, or contralateral breast
cancer. We required that the diagnosis of breast cancer had been
made in a hospital that, at the time, was taking part in any type of
registration of all breast cancer cases diagnosed in that hospital.
This eligibility criterion was necessary because the method of
selecting controls was based on calendar year of breast cancer
diagnosis. 98 patients with endometrial cancer after breast cancer
met these eligibility criteria.
Controls were women with breast cancer in whom endometrial
cancer had not been diagnosed. For each case patient, 3 controls
were sought. They were individually matched to the patient for
date of birth (within 3 years), date of diagnosis of breast cancer
(within 2 years), and pathology laboratory where the breast cancer
diagnosis was made. In addition, each control had to have survived,
with an intact uterus, for at least as long as the time between the
diagnoses of breast cancer and endometrial cancer in the
corresponding case. Furthermore, we required that the control had
not had a second primary cancer (other than carcinoma in situ of the
cervix, basal-cell carcinoma of skin, or contralateral breast cancer)
before the date the case patient developed endometrial cancer.
When more than 3 controls per case met the above criteria, we
selected those with the closest year of diagnosis of breast cancer,
and then closest date of birth, to the case. For endometrial cancer
patients whose breast cancer diagnoses were recorded in the cancer
registries, controls were drawn through the registries. For those
whose breast cancer registration records were not present in the
registries (since they were not operating at the time), controls were
selected through the Dutch Network and National Database for
Pathology. This database contains records of all cytological and
histological diagnoses made in the Netherlands, with computerised
data submission by the individual pathology laboratories. The
database was set up in 1977, and complete national coverage was
achieved in 1989. Control selection through this database was
allowed only if the breast cancer diagnosis of the case patient was
also recorded in the pathology database. 3 controls were found for
91 case patients, 2 controls for 5 cases, and 1 control for 2 cases.
For each case and her matched controls, full medical records
were obtained for detailed data abstraction. Information was
collected on stage of breast cancer, menopausal status at diagnosis
of breast cancer, occurrence of contralateral disease, vital status,
date of latest follow-up examination or date of death, and cause of
death. We recorded for each period of tamoxifen treatment the
starting date, the stopping date, and the dosage. The use of
radiotherapy, chemotherapy, and hormonal treatment other than
tamoxifen for breast cancer was also recorded. For each control, we
checked extensively whether she had undergone hysterectomy (in
which case she was excluded from the study). If necessary,
information was obtained from the patient’s general practitioner.
Complete information on all treatments, including periods of
tamoxifen use and dosage, was eventually available for all women.
For cases, we also sought information from the medical record on
the endometrial cancer diagnosis (stage of endometrial cancer, full
pathology report, treatment for endometrial cancer). All pathology
reports of endometrial cancer were reviewed centrally by one of us
(JB). If reports were incomplete or diagnosis uncertain, the slides
were reviewed by the local pathologist.
The relative risk of endometrial cancer associated with
tamoxifen use was estimated by comparison of the case patient’s
treatment history with that of her matched controls, by conditional
logistic regression methods.14 Relative risk estimates, two-sided
p values, and 95% CI were calculated with the microcomputer
programme EGRET (SERC, Seattle, Washington, USA);
comparisons between exposure categories were based on
likelihood-ratio tests. For analysis, only the treatment of case
*Breast cancer tBreast and endometnal cancers. tPremenopausal = last menstruation
< 3 mo previously; postmenopausal = last menstruation> > 1 yr previously. &sect;Treatment within
matched intervals; percentages add to more than 100 because of overlapping categories.
Table 1: Characteristics of case patients with endometrial
cancer after breast cancer and matched controls
patients during the time between the diagnoses of breast cancer and
of endometrial cancer was included. For controls, treatment was
studied for an equivalent time, starting with the date that breast
cancer was diagnosed. Total duration of tamoxifen use and total
dose were examined specifically as relevant factors in determining
risk. The cumulative dose of tamoxifen was grouped into quartiles
to calculate relative risks for each category in relation to the
reference group of patients not treated with tamoxifen. Tests for
trend in relative risk of endometrial cancer by duration (or
cumulative dose) of tamoxifen were calculated by fitting the actual
months (or mg) of use as a continuous variable in the logistic
regression analyses. To assess the effect of dose intensity,
duration-response slopes were estimated simultaneously for
women who had received daily doses of 40 mg and 30 mg or less.
Multivariate analyses were done to account for potentially
confounding effects of radiotherapy (yes/no), chemotherapy
(yes/no), hormonal treatment other than tamoxifen, and breast
cancer stage. For this purpose, hormonal treatment other than
tamoxifen was classified according to the expected effect on the
endometrium (oestrogen stimulation, yes/no; progestagenic
protection yes/no).
Results
Most of the women were over 55 years old and
postmenopausal when breast cancer was diagnosed (table
1). Date of birth was matched within 1 year for 78% of
controls and within 2 years for 94%. Most (74%) of the
endometrial cancers occurred in patients whose breast
cancer had been diagnosed in the 1980s. 89% of controls
matched cases within 1 year for diagnosis of breast cancer.
The median time between the diagnoses of breast cancer
and endometrial cancer was 34 (5-201) months. More cases
than controls were diagnosed with advanced breast cancer
(9 vs 4%, p==003, Fisher’s exact test). Controls were
slightly more likely than case patients to have received
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Table 2: Relative risk (RR) of endometrial cancer according to
total duration of tamoxifen use and cumulative dose
radiotherapy for breast cancer. However, there were no
significant differences between endometrial cancer patients
and controls in the types of treatments used for breast
cancer.
24% of the case patients and 20% of controls had used
tamoxifen at some time, and the relative risk of endometrial
cancer for women who had ever been treated with
tamoxifen compared with those who had not was 1 3 (95%
CI 0-7-24). The median duration of tamoxifen use was
higher for case patients than for controls (19 vs 13 months,
p=0 07). The risk of endometrial cancer increased with
duration (table 2). Women who had used tamoxifen for
more than 2 years had a 2.3 (0-9-5-9) times greater risk of
endometrial cancer than never users and the risk rose to 30
(0-6-15-8) for those treated for more than 5 years. None of
the risk estimates for categories of duration reached
significance, but the inclusion of duration of tamoxifen use
as a linear continuous variable in the logistic regression
model produced a significant trend (p = 0-049). The
cumulative dose of tamoxifen was also associated with the
risk of endometrial cancer (table 2, p for trend = 0 046). The
effect of tamoxifen was best fitted by including a binary
term (ever/never use) and the log-transformed duration of
tamoxifen use as a continuous variable in the model
RT=radiotherapy; HT=hormona therapy. *figs.‘6
Table 3: Characteristics of patients with endometrial cancer
according to use of tamoxifen
(p = 0-026). Similar duration and dose-response patterns
were found when analyses were restricted to the 89 women
(and their matched controls) in whom endometrial cancer
was diagnosed more than 1 year after the initial breast
cancer diagnosis. Adjustment for the variables
chemotherapy, radiotherapy, hormonal treatment other
than tamoxifen, and stage of breast cancer did not
substantially alter the risk estimates in table 2.
Of the 81 tamoxifen users in our study, most (59%)
had received daily doses of 40 mg, 17% received 30 mg, and
23% received 20 mg or less. We attempted to separate the
effects of dose intensity, duration of tamoxifen use, and
cumulative dose. The average dose of tamoxifen taken daily
did not affect the risk of endometrial cancer in a model
accounting for total duration of use (p=054). The
inclusion of dose intensity in the model hardly affected the
duration-response trend (005). To explore further the
effect of dose intensity, duration-response slopes were
fitted simultaneously for women who had received 40 mg
daily and those who received 30 mg or less. The relative risk
per year of tamoxifen use (with a multiplicative model,
based on actual months of use) was 1-22 for a daily dose of
30 mg or less and 1-24 for 40 mg (tests for linear trend
p = 0 18 and p = 0 10, respectively). The two doses did not
differ in duration-response trends (p=0’73).
Within the case group, we studied whether the
endometrial cancers in women who had used tamoxifen had
different characteristics from those diagnosed in women
who had never been treated with the drug (table 3). The
stage distributionsl5 and morphology of the endometrial
cancers in these two groups showed no striking differences.
During median follow-up of 15 months after the diagnosis
of endometrial cancer, none of the tamoxifen-treated
women died of this cancer. Median follow-up in never users
was 29 months. 2-year actuarial survival after the diagnosis
of endometrial cancer was similar for women who had
received breast cancer treatment with tamoxifen and for
those who had never received the drug (68% and 71%,
respectively).
Discussion
Our results support the hypothesis that use of tamoxifen
increases the risk of endometrial cancer. We found a
significant trend in risk of endometrial cancer with total
duration of tamoxifen treatment, whatever the dose
intensity.
In interpreting our results we considered several
potential sources of bias. Increased medical surveillance in
tamoxifen users, as well as the presence of gynaecological
symptoms due to tamoxifen treatment (eg, vaginal
bleeding) might lead to earlier diagnosis of endometrial
cancer in such women than in untreated patients, which
might result in a spurious association between tamoxifen
and endometrial cancer. We found no evidence for such
bias. First, the stage distribution of the endometrial cancers
did not differ between ever and never users. Furthermore,
women who had used tamoxifen for a year or less did not
have an increased risk of endometrial cancer, and in the
(small) subgroup of endometrial cancers diagnosed within 1
year from the breast cancer diagnosis we found no
association with tamoxifen use.
Since the Netherlands did not have a nationwide cancer
registry in the 1970s and early 1980s, some patients with
endometrial cancer after breast cancer were not eligible for
our study, solely because there was no sampling frame for
control breast cancer patients diagnosed in the same
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calendar period. Although this feature reduces the study’s
power, we do not believe that it introduces bias to our
results. For each endometrial cancer case included in the
study, all the corresponding matched controls were drawn
from a source that also included the breast cancer diagnosis
of the case patient. Given this design, selection bias could
arise only in the unlikely event that an association between
tamoxifen and risk of endometrial cancer depended on the
presence of a regional cancer registry at the time of the
breast cancer diagnosis.
By matching controls with case patients, we incorporated
adjustment for important confounders such as age and
calendar year at breast cancer diagnosis. The additional
matching, according to the pathology laboratory where the
breast cancer diagnosis was made, was introduced for
practical reasons, and enabled us to include case patients
with a long time between the diagnoses of endometrial and
breast cancer. However, matching for pathology laboratory
may have resulted in greater similarity in treatment between
case patients and controls than would otherwise have been
observed. This notion is not just theoretical, since the
introduction date of tamoxifen, the indications for its use,
and the dose and duration of administration have varied
between regions in the Netherlands. Overmatching may
thus have led us to underestimate risk of endometrial cancer
associated with tamoxifen use. On the other hand, we may
have adjusted for determinants of regional differences in
incidence of endometrial cancer. Since the possibility of
overmatching cannot be excluded, our risks must be viewed
as minimum estimates of the true effect of tamoxifen.
Evidence for an association between the use of tamoxifen
and risk of endometrial cancer has, to date, come from only
two other studies. In the Stockholm trial4 the relative risk
was 6-4 (p<0-01) for women who received 40 mg/day
tamoxifen for at least 2 years compared with untreated
women. In the Danish studies8,9 there was a non-significant
three-fold excess in women who received 30 mg daily for 48
weeks compared with untreated women. These estimates
were based on 15 and 20 cases of endometrial cancer,
respectively. Our risk estimates, based on much larger
numbers of cases, are somewhat lower than these previous
estimates (relative risk 2-3 for 2 years’ use, 3-0 for > 5 years’
use), possibly because of overmatching in the study design.
In several other large trials of adjuvant tamoxifen therapy,
no increased risk of endometrial cancer has been
observed.3,7,16 However, no full statistical evaluation of
second cancer incidence in these trials has been published,
and incomplete registration of second cancers, or lack of
sufficient follow-up time, may have led to negative findings
in some trials.
The observation of increased risk of endometrial cancer
after tamoxifen treatment is biologically plausible and may
be explained as a partial oestrogen-agonistic effect of
tamoxifen on the endometrium.17,18 Endometrial lesions,
such as hyperplasia, are more common in breast cancer
patients who have received a cumulative dose of tamoxifen
of 15 g or more than in those receiving smaller doses.19
Interestingly, in our study the risk of endometrial cancer
was also increased only after cumulative doses above 15 g. It
has been suggested that the oestrogenic effect of tamoxifen,
especially the proliferative effect on the endometrium,
depends upon the dose intensity of the drug. Our results do
not support this suggestion. We must emphasise, however,
that few women in our study received 30 mg daily or less,
and neither of the duration-response trends for the two
subcategories of tamoxifen dose intensity reached statistical
significance. Numbers did not permit a separate risk
calculation for women who took 20 mg per day, which is the
dose used in the continuing chemoprevention trials. The
Danish study8,9 also reported increased risk (though not
significantly) of endometrial cancer at a dose of 30 mg.
Oestrogenic effects of a daily dose of 20 mg tamoxifen on the
postmenopausal vagina have also been reported .20,21 With
regard to a similar association, that between
postmenopausal oestrogen replacement therapy and risk of
endometrial cancer, elevated risks have also been reported
for the lowest dose levels.22
It has been postulated that any increase of endometrial
cancer risk due to the oestrogenic effects of tamoxifen
would yield a high proportion of highly differentiated,
prognostically favourable tumours, as has been observed
with endometrial carcinomas associated with oestrogen
replacement therapy.23-25 We found no substantial
differences in histological features of the endometrial
cancers diagnosed in tamoxifen-treated patients and in
non-treated women. The only suggestion of a difference
was in the proportion of well-differentiated tumours (52%
in tamoxifen users and 32% in women not treated with
tamoxifen). Since the histological slides of endometrial
cancers were not reviewed centrally, this finding must be
interpreted cautiously. In Magriples and colleagues’
study26 of the clinical and histological features of
endometrial cancers in breast cancer patients who had or
had not received tamoxifen, there was a significant excess of
poorly differentiated tumours in the tamoxifen-treated
group’26 However, the number of tamoxifen users in that
study, as well as in ours, was small (15 and 23, respectively),
and in both studies the age distribution of the tamoxifen-
treated group differed from that in the untreated patients. A
much larger patient population would be needed to refute
or confirm an association between tamoxifen use and
specific histological characteristics of endometrial cancer.
Increased risk of endometrial cancer after tamoxifen use
will cause some morbidity in breast cancer patients treated
with the drug. However, the proven clinical benefit of
tamoxifen in controlling breast cancer1 clearly outweighs
the modest increase of endometrial cancer risk.
Endometrial cancer has a more favourable prognosis than
breast cancer, so no patient should be denied tamoxifen
treatment of her breast tumour because of anticipated
adverse effects on the endometrium.
The issue of whether tamoxifen should be used to
prevent cancer in healthy women, who do not have a
medical need for treatment, is different, however. Even if,
at the population level, the postulated reduction in the
incidence of breast cancer were to outweigh the apparently
increased risk of endometrial cancer, it is debatable whether
the use of a medical intervention can be justified when it
prevents breast cancer in some women at the cost of
inducing endometrial cancer in others. This issue will
continue to provoke discussion in the medical
community,27-29 until more is known about tamoxifen’s
long-term benefits and adverse effects. Further studies are
needed to quantify the risk for women taking 30 mg or 20 mg
per day, to assess the effect of very long durations of use (5
years or more), and to determine the risk for ex-users.
Meanwhile, we believe that, on the basis of our results,
physicians should be alert to the higher risk of endometrial
cancer in all women using tamoxifen, both breast cancer
patients and healthy participants in prevention trials.
Regular gynaecological examinations may be worth while
for long-term users.
452
We thank Dr I JAM G Casparie-van Velsen (Dutch Network and
National Database for Pathology), ProfH J A Collette (Department of
Epidemiology, University of Utrecht), and the hospital cancer registries of
the Netherlands Cancer Institute and the Dr Daniel den Hoed Cancer
Center for making control selection possible; the treating specialists for
providing access to patients’ medical charts; and the abstracting teams
from the regional cancer registries for data collection. This study was
supported partly by a grant (NKI 88-11) from the Dutch Cancer Society.
References
1 Early Breast Cancer Trialists’ Collaborative Group. Systemic
treatment of early breast cancer by hormonal, cytotoxic, or immune
therapy: 133 randomised trials involving 31 000 recurrences and 24 000
deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
2 CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and
tamoxifen as adjuvant therapies in the management of breast cancer.
Br J Cancer 1988; 57: 604-07.
3 Fisher B, Constantino J, Redmond C, et al. A randomized trial
evaluating tamoxifen in the treatment of patients with node-negative
breast cancer who have estrogen-receptor-positive tumors. N Engl J
Med 1989; 320: 489-84.
4 Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in
early breast cancers: occurrence of new primary cancers. Lancet 1989; i:
117-20.
5 Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer
with tamoxifen: an update on the Royal Marsden pilot programme.
Eur J Cancer 1990; 26: 680-84.
6 Fisher B, Redmond C. New perspective on cancer of the contralateral
breast: a marker for assessing tamoxifen as a preventive agent. J Natl
Cancer Inst 1991; 83: 1278-80.
7 Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role
of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;
83: 1450-59.
8 Andersson M, Storm HH, Mouridsen HT. Incidence of new primary
cancers after adjuvant tamoxifen therapy and radiotherapy for early
breast cancer. J Natl Cancer Inst 1991; 83: 1013-17.
9 Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of
adjuvant tamoxifen treatment and radiotherapy for early breast cancer.
Acta Oncol 1992; 31: 259-63.
10 Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients
with metastatic breast cancer: a review. J Clin Oncol 1991; 9: 1283-97.
11 LOK/Coordinating Council of Comprehensive Cancer Centers, ed.
Incidence of cancer in the Netherlands 1989: First report of the
Netherlands Cancer Registry. Utrecht: LOK, 1992.
12 Muir C, Waterhouse J, Mack T, et al, eds. Cancer incidence in five
continents, vol V, no 88. Lyon: IARC Scientific Publications, 1987.
13 Collette HJA, Day NE, Rombach JJ, De Waard F. Evaluation of
screening for breast cancer in a non-randomised study (the DOM
project) by means of a case-control study. Lancet 1984; i: 1224-26.
14 Breslow NE, Day NE. Statistical methods in cancer research: the
analysis of case-control studies, vol 1, no 32. Lyon: IARC Scientific
Publications, 1980.
15 Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990;
75: 287-88.
16 Stewart HJ, Knight GM. Tamoxifen and the uterus and endometrium.
Lancet 1989; 1: 375-76.
17 Gottardis MM, Robinson SP, Satyaswaroop PS, Jordan VC.
Contrasting actions of tamoxifen on endometrial and breast cancer
tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-15.
18 Boccardo F, Guarnieri D, Rubagotti A, et al. Endocrine effects of
tamoxifen in postmenopausal breast cancer patients. Tumori 1984; 70:
61-68.
19 De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G,
De Muylder E. Endometrial lesions in patients undergoing tamoxifen
therapy. Int J Gynaecol Obstet 1991; 36: 127-30.
20 Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like
effect of tamoxifen on vaginal epithelium. BMJ 1977; i: 1351-52.
21 Boccardo F, Bruzzi P, Rugagotti A, et al. Estrogen-like action of
tamoxifen on vaginal epithelium in breast cancer patients. Oncology
1981; 38: 281-85.
22 Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent
disease and prolong life in postmenopausal women. Ann Intern Med
1992; 117: 1016-37
23 Elwood JM, Boyes DA. Clinical and pathological features and survival
of endometrial cancer patients in relation to prior use of estrogens.
Gynecol Oncol 1980; 10: 173-87.
24 Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of
cancer registries. Am J Epidemiol 1986; 124: 434-41.
25 Collins J, Donner A, Allen LN, Adams O. Oestrogen use and survival
in endometrial cancer. Lancet 1980; i: 961-14.
26 Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade
endometrial carcinoma in tamoxifen-treated breast cancer patients.
J Clin Oncol 1993; 11: 485-90.
27 Fugh-Berman A, Epstein S. Tamoxifen: disease prevention or disease
substitution? Lancet 1992; 340: 1143-45.
28 Powles TJ. The case for clinical trials of tamoxifen for prevention of
breast cancer. Lancet 1992; 340: 1145-47.
29 Neven P. Tamoxifen and endometrial lesions. Lancet 1993; 342: 452.
Short reports
&agr;1-antitrypsin deficiency in intracranial
aneurysms and cervical artery dissection
The pathogenesis of ruptured intracranial aneurysms and
cervical artery dissections is poorly understood but may be
similar in these two disorders. We report four patients with
&agr;1-antitrypsin deficiency who developed a ruptured intracranial
aneurysm or spontaneous dissection of the cervical internal
carotid artery. Three patients were heterozygous for the
deficient allele (PiMZ or PiGZ) and one was homozygous
(PiZZ). A deficiency of &agr;1-antitrypsin or one of the other
protease inhibitors could result in degradation of the arterial
wall through an imbalance between proteolytic enzymes and
their inhibitors, thereby predisposing the arterial wall to
dissection or aneurysm formation.
Lancet 1994; 343: 452-53
The pathogenesis of ruptured intracranial aneurysms and
spontaneous cervical artery dissections is not well
understood but an underlying arteriopathy is usually
suspected. Except for some patients with fibromuscular
dysplasia or certain heritable connective tissue disorders,
investigations into the nature of this arteriopathy have been
unsuccessful. Deficiencies of ol-antitrypsin or other
inhibitors of proteolytic enzymes may have a role in the
development of abdominal arterial aneurysms.2,3 Such
deficiency could undermine the integrity of the vascular
extracellular matrix, predisposing the arterial wall to
dissection or aneurysm formation. We report a group of
patients with ex1-antitrypsin deficiency who developed
aneurysmal subarachnoid haemorrhage or spontaneous
cervical artery dissection.
All patients with el-antitrypsin deficiency, who were
evaluated at the Mayo Clinic between 1976 and 1992, were
identified through a computerised and coded diagnostic
index. This group consisted of 168 women and 194 men
(mean age 48 years). All had symptoms of al-antitrypsin
deficiency, which had been diagnosed with similar methods
throughout the study period. During this time, about 140
patients with spontaneous carotid dissection and 1250
patients with aneurysmal subarachnoid haemorrhage were
seen at our institution.
